Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;37(11):1493-1503.
doi: 10.1177/08850666221121593. Epub 2022 Aug 25.

Effect of Awake Prone Positioning in non-Intubated COVID-19 Patients with Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-Analysis

Affiliations
Review

Effect of Awake Prone Positioning in non-Intubated COVID-19 Patients with Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-Analysis

Hanyujie Kang et al. J Intensive Care Med. 2022 Nov.

Abstract

Background: Awake prone positioning (APP) has been considered as a feasible treatment for patients with acute hypoxemic respiratory failure in non-intubated coronavirus disease 2019 (COVID-19). However, the efficacy and safety of APP remain uncertain. This meta-analysis aims to assess the effect of APP on intubation rate and mortality in COVID-19 patients with acute respiratory failure.

Methods: Relevant studies published from January 1, 2020, to June 17, 2022, were systematically searched. The primary outcomes were the intubation rate and mortality; the secondary outcome was the incidence of adverse events.

Results: Of 5746 identified publications, 22 were eligible for inclusion in the meta-analysis (N = 5146 patients). In comparison to the non-APP group, APP could decrease the intubation rates (OR 0.64; 95% CI 0.48-0.83; P = .001), particularly in the subgroup of the daily median duration of APP > 8 h and in the subgroup of receiving high flow nasal cannula (HFNC) or non-invasive ventilation (NIV). Patients treated with APP were associated with lower mortality rates (OR 0.61; 95% CI 0.45-0.81; P = .0008), but no mortality benefit was found in the APP group in the subgroup of randomized controlled trials (RCTs). No significant difference was found in the incidence of adverse events between the groups (OR 1.13; 95% CI 0.75-1.71; P = .56).

Conclusion: Our results demonstrated that APP could be an effective strategy to avoid intubation without detrimental effects in non-intubated patients with COVID-19, especially for patients requiring HFNC or NIV, and the daily APP duration with the target of minimally eight hours was suggested. In the subgroup of RCTs, the pooled results did not demonstrate any benefit of APP on mortality. Given the limited number of RCTs, further high-quality RCTs are needed to confirm the results.

Inplasy registration number: INPLASY2021110037.

Keywords: COVID-19; acute respiratory failure; awake prone positioning; intubation rate; mortality.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flow chart of the study selection.
Figure 2.
Figure 2.
Forest plot for subgroup analysis of intubation rate according to randomized controlled trials or observational studies.
Figure 3.
Figure 3.
Forest plot for subgroup analysis of intubation rate according to the daily median duration of APP.
Figure 4.
Figure 4.
Forest plot for subgroup analysis of intubation rate according to the non-invasive respiratory support methods.
Figure 5.
Figure 5.
Forest plot for subgroup analysis of mortality according to randomized controlled trials or observational studies.
Figure 6.
Figure 6.
Forest plot showing the effect of awake prone positioning on the incidence of adverse events of non-intubated COVID-19 patients with acute hypoxemic respiratory failure.

Similar articles

Cited by

References

    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. Jama. 2020;323(13):1239–1242. - PubMed
    1. WHO. COVID-19 Clinical management: living guidance. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.
    1. Grasselli G, Zangrillo A, Zanella A, et al.Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. Jama. 2020;323(16):1574–1581. - PMC - PubMed
    1. Xie J, Wu W, Li S, et al.Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. Intensive Care Med. 2020;46(10):1863–1872. - PMC - PubMed
    1. Cummings MJ, Baldwin MR, Abrams D, et al.Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. - PMC - PubMed